Legendary hedge fund manager Paul Tudor Jones said Thursday that he expects a Democratic sweep in November and that will send markets for a wild ride over the next 12 months.
Keep Reading →
October 22 - Hedge Funds, Insider Trading - Comments
Biotechnology is a very interesting industry to invest in, but also very complex.
Keep Reading →
May 1 - Hedge Funds, News - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
March 30 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
March 16 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
March 6 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
February 22 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
January 26 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
January 26 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
January 26 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
January 26 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
January 23 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
January 8 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
December 4 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
December 1 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
November 21 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
November 9 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
October 27 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
October 23 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
October 6 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
October 3 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
September 29 - Hedge Funds - Comments
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Keep Reading →
September 11 - Hedge Funds - Comments
OrbiMed Advisors LLCOrbiMed Capital GP IV LLCSamuel D.
Keep Reading →
August 24 - Hedge Funds - Comments
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of...
Keep Reading →
August 23 - Hedge Funds - Comments
OrbiMed Advisors LLCOrbiMed Capital GP III LLCSamuel D.
Keep Reading →
August 16 - Hedge Funds - Comments
OrbiMed Advisors LLCOrbiMed Capital GP IV LLCSamuel D.
Keep Reading →
August 11 - Hedge Funds - Comments
OrbiMed Advisors LLCOrbiMed Capital GP III LLCSamuel D.
Keep Reading →
August 9 - Hedge Funds - Comments
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of...
Keep Reading →
August 3 - Hedge Funds - Comments
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of...
Keep Reading →
July 7 - Hedge Funds - Comments
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of...
Keep Reading →
June 22 - Hedge Funds - Comments
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of...
Keep Reading →
May 8 - Hedge Funds - Comments
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because ...
Keep Reading →
April 28 - Hedge Funds - Comments
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of...
Keep Reading →
March 22 - Hedge Funds - Comments
A freshly-amended 13D filing with the US SEC showed that Sam Isaly’s OrbiMed Advisors has sold some of its shares of Affimed N.V.
Keep Reading →
September 27 - Hedge Funds, News - Comments
Sam Isaly’s OrbiMed Advisors recently filed a Form 13D with the Securities and Exchange Commission in which reported the acquisition of 3.07 million shares of Steadymed Ltd...
Keep Reading →
August 14 - Hedge Funds, News - Comments
Samuel Isaly’s OrbiMed Advisors recently filed a 13D filing with the SEC in which it reported owning 2.18 million common shares of Loxo Oncology Inc.
Keep Reading →
August 8 - Hedge Funds, News - Comments
According to a recent 13G filing with the US Securities and Exchange Commission Sam Isaly’s Orbimed Advisors has increased its stake in Cynapsus Therapeutics Inc.
Keep Reading →
July 12 - Hedge Funds, News - Comments
Samuel Isaly’s Orbimed Advisors recently filed a Form 13D with the Securities and Exchange Commission, in which it reported a new stake in Selecta Biosciences Inc (NASDAQ:SELB...
Keep Reading →
July 8 - Hedge Funds, News - Comments
Samuel Isaly just cannot get enough of Ascendis Pharma A/S (NASDAQ:ASND).
Keep Reading →
July 5 - Hedge Funds, News - Comments
Samuel Isaly's OrbiMed Advisors has stepped up its interest in Ascendis Pharma A/S (NASDAQ:ASND) as reported in a recently-amended filing with the Securities and Exchange Commission...
Keep Reading →
June 26 - Hedge Funds, News - Comments
Affimed NV (NASDAQ:AFMD) is the subject of a 13D filing from Samuel Isaly's OrbiMed Advisors, which shows that the investment firm has sold off some of its stake in the company...
Keep Reading →
March 31 - Hedge Funds, News - Comments
According to the Schulte, Roth & Zabel’s Activist Investing 2015 Annual Review, 344 companies were targeted by activist investors in 2014, as compared with 291 recorded a year...
Keep Reading →
December 28 - Hedge Funds, News - Comments
You don’t necessarily need millions of dollars to invest like an activist investor such as Carl Icahn or Bill Ackman.
Keep Reading →
November 23 - Hedge Fund Analysis, Hedge Funds, News - Comments
It is easy to imagine that hedge funds would not reveal their equity positions if it were not for reporting requirements enforced by the Securities and Exchange Commission.
Keep Reading →
November 20 - Hedge Fund Analysis, Hedge Funds, News - Comments
It is commonly known that most hedge fund investors reveal their positions through 13F quarterly filings, but 13D filings tend to provide more insights about their stances on...
Keep Reading →
November 2 - Hedge Fund Analysis, Hedge Funds, News - Comments
As U.S equities have plummeted on global-growth worries, confident hedge funds and other investors have started piling up more shares of companies that are trading on the cheap...
Keep Reading →
October 5 - Hedge Funds, Market Movers, News - Comments
Samuel Isaly’s OrbiMed Advisors is a healthcare fund with $15 billion worth of assets under management.
Keep Reading →
August 16 - Hedge Fund Analysis, Hedge Funds, News - Comments
Dennis Purcell’s Aisling Capital and Samuel Isaly’s OrbiMed Advisors have initiated new positions in Cynapsus Therapeutics Inc (NASDAQ:CYNA). In new filings with the U.S.
Keep Reading →
July 7 - Hedge Funds, News - Comments
Glaukos Corp (NYSE:GKOS) is an $870 million developer of products for the treatment of glaucoma, which conducted its IPO last week with 6.90 million shares at $18.00 per unit.
Keep Reading →
July 1 - Hedge Funds, News - Comments
Headquartered in Connecticut, Sarissa Capital Management was founded by Alexander J. Denner in 2012. Prior to this, Mr.
Keep Reading →
April 15 - Hedge Funds, News - Comments
